EMA Authorised: Elocta (efmoroctocog alfa) — Swedish Orphan Biovitrum AB (publ)

View source ↗

Summary

The European Medicines Agency authorised Elocta (efmoroctocog alfa) for Hemophilia A; decision date: 25/04/2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Elocta (efmoroctocog alfa)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: Swedish Orphan Biovitrum AB (publ). Decision date: 25/04/2025